Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Mutations in CSF1R and Other Receptor Tyrosine Kinases Associated with Histiocytic Neoplasms

  • By

  • Benjamin H. Durham

  • Estibaliz Lopez Rodrigo

  • Jennifer Picarsic

  • David Abramson

  • Veronica Rotemberg

  • Steven De Munck

  • Erwin Pannecoucke

  • Sydney X. Lu

  • Alessandro Pastore

  • Akihide Yoshimi

  • Diana Mandelker

  • Ozge Ceyhan-Birsoy

  • Gary A. Ulaner

  • Michael Walsh

  • Mariko Yabe

  • Kseniya Petrova-Drus

  • Maria E. Arcila

  • Marc Ladanyi

  • David B. Solit

  • Michael F. Berger

  • David M. Hyman

  • Mario E. Lacouture

  • Caroline Erickson

  • Ruth Saganty

  • Michelle Ki

  • Ira J. Dunkel

  • Vicente Santa-María López

  • Jaume Mora

  • Julien Haroche

  • Jean-Francois Emile

  • Olivier Decaux

  • Frederic Geissmann

  • Savvas N. Savvides

  • Alexander Drilon

  • Eli L. Diamond

  • Omar Abdel-Wahab

  • September 1, 2026

Share

Clinical Scorecard: Correction Notice: Mutations in CSF1R and Other Receptor Tyrosine Kinases Associated with Histiocytic Neoplasms

At a Glance

CategoryDetail
ConditionHistiocytic Neoplasms
Key MechanismsMutations in CSF1R and other receptor tyrosine kinases
Target PopulationPatients with histiocytic neoplasms
Care SettingClinical research and genetic analysis

Key Highlights

  • Correction of actin lane in Extended Data Fig. 10f
  • Inclusion of full-length, uncropped blot in Source Data
  • Updated figure provides accurate representation of data

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

            • by Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan-Birsoy, Gary A. Ulaner, Michael Walsh, Mariko Yabe, Kseniya Petrova-Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa-María López, Jaume Mora, Julien Haroche, Jean-Francois Emile, Olivier Decaux, Frederic Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel-Wahab

            • September 1, 2026

            Related Content

            Coding for Ocular Tumors

            Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

            Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis

            Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features